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Abstract
Iatrogenic calcinosis cutis occurs when insoluble calcium salts deposit in cutaneous and
subcutaneous tissue. Iatrogenic calcinosis cutis is a rare complication from a variety of medical
interventions, most commonly due to extravasated intravenous calcium-containing solutions.
We present a severe case of iatrogenic calcinosis cutis in a patient with end-stage renal disease
and an elevated serum calcium-phosphate product. Iatrogenic calcinosis cutis has a wide range
of clinical presentations. Either subclinical or clinically noticeable extravasations may cause
mild to severe calcinosis cutis. Patients with increased serum calcium and phosphate may be at
increased risk of iatrogenic calcinosis cutis. Treatment options include conservative,
pharmacologic, or surgical management.
Categories: Dermatology, Internal Medicine, Nephrology
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Introduction
Calcinosis cutis is defined as insoluble calcium salt deposition in cutaneous and subcutaneous
tissue [1,2]. There are five subtypes of calcinosis cutis based on etiology: dystrophic,
metastatic, calciphylaxis, idiopathic, and iatrogenic. Dystrophic calcinosis cutis is due to local
tissue damage secondary to trauma, infection, neoplastic processes, or a variety of connective
tissue disorders. Metastatic calcinosis cutis, a rare manifestation, occurs secondary to systemic
calcium and phosphate abnormalities, classically occurring in chronic renal failure.
Calciphylaxis, a related yet distinct entity from metastatic calcinosis cutis, occurs when small
and medium-sized blood vessels in the dermis and subcutaneous fat calcify. Idiopathic
calcinosis cutis occurs without known local tissue injury or metabolic disorders [1,2]. Lastly,
iatrogenic calcinosis cutis most commonly occurs from extravasation of calcium or phosphate-
containing solutions [3]. Iatrogenic calcinosis cutis has been reported in patients undergoing
electroencephalography or electromyography with prolonged periods of exposure to saturated
calcium-containing electrode paste [4-6]. Iatrogenic calcinosis cutis has also occurred in
patients receiving subcutaneous injections of para-aminosalicylic acid, solid organ transplant
recipients, and neonates receiving numerous heel venipuncture sticks [1,2]. We present a severe
case of iatrogenic calcinosis cutis after extravasation of calcium gluconate solution.
Case Presentation
A 55-year-old woman with no underlying connective tissue disease and a past medical history
of hemodialysis-dependent end-stage renal disease due to type 2 diabetes mellitus and
hypertension was hospitalized for left lower extremity cellulitis who requested inpatient
removal of a right forearm plaque. The lesion location corresponded with the site of an
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days prior during a previous hospitalization requiring urgent hemodialysis to treat
hyperkalemia. The patient described an initial burning sensation during the extravasation, but
the subsequent calcification, which developed over a few days, was insensate. 
On examination, a yellow-white, rock-hard indurated plaque measuring approximately 4 × 3 cm
with overt mineral deposits was found on the right distal flexor forearm (Figure 1). The bandage
next to the lesion in question is to remedy an unrelated trauma-induced injury. At the time of
physical examination, her serum corrected calcium level was 10.1 mg/dl (normal range: 8.5-10.1
mg/dl) and phosphate level was 7.6 mg/dl (normal range: 2.5-4.9 mg/dl). A clinical diagnosis of
iatrogenic calcinosis cutis was made based on the infusion history and the localized
calcification. Outpatient surgical intervention was chosen given her severe presentation;
however, the patient expired from a fatal arrhythmia while waiting for the procedure.
FIGURE 1: Indurated plaque on the right flexor forearm at the
site of extravasated calcium gluconate infusion.
Discussion
Extravasation of any calcium-containing peripheral infusion can cause iatrogenic calcinosis
cutis [2,3,7]. Extravasations often lead to abrupt symptoms of erythema, tenderness,
induration, and edema; however, subclinical extravasations may lack these initial symptoms
and still present with calcinosis. Calcinosis typically develops within two weeks as yellow-white
papules, plaques, or nodules with possible tissue necrosis or ulceration. Calcinosis can occur
despite removal of the intravenous line suspected of extravasation [3,7].
Subcutaneous injection of calcium-containing solutions in rats led to formation of mineralized
plaques with a total calcium content 100 times greater than the amount of calcium infused [8].
Therefore, the hypothesized pathogenesis of iatrogenic calcinosis cutis is mineralization of
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calcium derived from extravasated calcium solutions and cellular release of calcium from local
tissue damage [3,8-10]. This mechanism may explain the development of iatrogenic calcinosis
cutis in subclinical extravasations and the variability in degree of calcinosis among patients. An
elevated calcium-phosphate product is most associated with metastatic calcinosis cutis and
calciphylaxis [1,2]. However, authors have suggested an elevated calcium-phosphate product
may increase susceptibility to iatrogenic calcinosis cutis, which may have contributed to our
patient’s severe calcinosis [9]. Lastly, the presence of collagen, which facilitates calcium
phosphate deposition, is believed to be a critical factor in the pathogenesis of iatrogenic
calcinosis cutis. Histologic samples of affected tissue show calcium deposits in close proximity
to degenerated collagen fibers within the dermis [3,10].
Prevention of extravasation is the most important mitigating factor in developing iatrogenic
calcinosis cutis. Use of a central line or diluted calcium and phosphate solutions may reduce
rates of iatrogenic calcinosis cutis [9]. Calcium chloride, an inorganic calcium salt, has a higher
risk of skin necrosis and adverse effects from extravasation compared to calcium gluconate, an
organic calcium salt [11,12]. Theories suggest this heightened risk from calcium chloride is most
related to increased dissociation tendency and thus elevated local ionized calcium
concentration [11,12]. Local ionized calcium concentration appears to be of greater significance
than other factors such as pH or osmolarity [12,13].
Immediate management of clinically recognized extravasations is not well defined.
Intralesional triamcinolone acetonide and hyaluronidase was shown to reduce severity and rate
of development of calcinosis cutis following extravasated calcium-containing solutions in
rabbit models [14,15]. However, there is scant human evidence for these therapies, and
conservative measures, such as elevation of the extravasation site and cold compresses,
predominate in current practice [11,16].
There is no standardized treatment for iatrogenic calcinosis cutis once it occurs [16,17].
Treatment regimens are largely derived from case reports. Options include conservative,
pharmacologic, or surgical management. Typically, less severe cases of iatrogenic calcinosis
cutis resolve in two to six months with conservative local wound care alone [3]. Sodium
thiosulfate, a medication utilized systemically for calciphylaxis or locally for dystrophic
calcification, has cation chelating properties allowing for soluble calcium thiosulfate complex
formation [9]. Two separate case reports, including a six-year-old boy and a sixty-year-old man
with iatrogenic calcinosis cutis, describe topical sodium thiosulfate treatment leading to
complete resolution of calcinosis cutis as described in Table 1 [9,18]. There are no other
effective pharmacologic therapies studied specifically for iatrogenic calcinosis cutis. Other
pharmacologic options are derived from treating different forms of calcinosis cutis, including
bisphosphonates, diltiazem, warfarin, minocycline, ceftriaxone, aluminum hydroxide,
probenecid, intralesional corticosteroids, and intravenous immunoglobulin [9,11,17]. Severe
cases, such as our case patient, require surgical intervention [2,3].
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Author, year
of publication
García-García et al., 2017 [9] Abbott et al., 2020 [18]




prophylactic thyroidectomy due to carrier
status of RET proto-oncogene and family
history of multiple endocrine neoplasia type 2
Chronic obstructive pulmonary disease on tacrolimus for right-sided
lung transplant three months prior to case presentation date
Reason for
presentation
Severe hypocalcemia Cardiac arrest secondary to a complicated bronchoscopy





Left antecubital fossa infusion led to phlebitis
prompting removal and placement in right
antecubital fossa which also led to phlebitis
Left dorsal hand. No initial signs or symptoms as patient required





Bilateral calcinosis occurred within a few
days of infusion





On bilateral antecubital fossae, multiple
erythematous nodules with extrusion of
yellow calcified substance







Severe motility impairment and pain Asymptomatic
Treatment
Compounded 10% topical sodium thiosulfate
in a water-in-oil emulsion cold cream applied
every morning and night under occlusion




After three months of treatment: dramatic
improvement in skin lesions and motility.
After six months of treatment: normal skin
appearance and motility
After one month of treatment: 95% reduction in plaque size. After
two months of treatment: 99% plaque resolution. At four-month
assessment (after an additional one to two weeks of focal
applications to residual white spots): complete resolution
Adverse
effects
None reported None reported
TABLE 1: Comparison of two published cases of iatrogenic calcinosis cutis
successfully treated with topical sodium thiosulfate
2020 Rumancik et al. Cureus 12(8): e9712. DOI 10.7759/cureus.9712 4 of 6
Conclusions
Iatrogenic calcinosis cutis is an uncommon manifestation most commonly occurring after
extravasation of calcium-containing solutions. Clinicians should be aware of the variable time
course and severity resulting from either clinically insignificant or noticeable extravasations.
Treatment should be considered immediately after extravasations and upon development of
calcinosis cutis. However, no agreed upon treatment protocol for these clinical scenarios exists.
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